Pharmaceuticals News

DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje a expansão da sua equipe executiva....

ノースカロライナ州ダーラム発, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 世界有数の医薬品開発業務受託機関 (CRO) であるフォートリア (Fortrea) (NASDAQ: FTRE) (以下「同社」) は本日、経営陣の拡充を発表した。これまでフォートリアの最高医療責任者 (CMO) 兼臨床薬理サービス (CPS)...

Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026. Sanofi annonce avoir déposé son Document...

Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F...

Ricavi netti consolidati per l’esercizio 2025 pari a € 2.618,4 milioni, +11,8% o +8,3% a perimetro omogeneo(3) e a cambi costantiEBITDA(1) pari a € 991,1 milioni, +14,5%, con un’incidenza sui ricavi...

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA +14.5%, ADJUSTED NET INCOME +14.5%

CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its...

Media ReleaseCOPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...

Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025,...

SAN DIEGO and SUZHOU, China, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based...